A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single and Multiple Doses of ENC1018 in Healthy Adult Subjects
Sponsor: EnnovaBio Australia Pharmaceuticals Pty Ltd
This PHASE1 trial investigates Healthy and is currently completed. EnnovaBio Australia Pharmaceuticals Pty Ltd leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EnnovaBio Australia Pharmaceuticals Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .